[Ciprofloxacin in the prevention and treatment of surgical infections]. / Primenenie tsiprofloksatsina v profilaktike i lechenii khirurgicheskikh infektsii.

A clinico-laboratory study on ciprofloxacin made by Bayer (Germany) was applied to patients with extended posttraumatic wounds and performed with the aim of preventing postoperative purulent complications in patients operated on the organs of the gastrointestinal tract. In the both groups ciprofloxacin was administered orally in doses of 500 and 1000 mg and intravenously in a dose of 200 mg. The results of the assay on ciprofloxacin sensitivity of the isolates from the wound excretion and urine showed that they were more sensitive to ciprofloxacin than to aminoglycosides and cephalosporins. 15 minutes after the intravenous administration the serum concentration of ciprofloxacin amounted to 7.5 +/- 0.9 micrograms/ml and in 6 hours it was equal to 0.45 +/- 0.45 micrograms/ml, the mean concentrations of ciprofloxacin being attained in the bile (8.7 +/- +/- 3.9 micrograms/ml), gallbladder wall (5.5 +/- 3.8 micrograms/g), liver (0.73 micrograms/g), muscles (1.93 micrograms/g) and tendon (0.15 microgram/g). After the oral administration in a dose of 500 mg ciprofloxacin was detected in the blood serum in an amount of 2.0 +/- 0.7 micrograms/ml in 1 hour and in an amount of 0.9 +/- 0.13 micrograms/ml in 6 hours. After the drug oral administration in a dose of 1000 mg the maximum concentrations were: 6.34 +/- 4.2 micrograms/ml on the average and 2.1 +/- 0.8 micrograms/ml in 6 hours (0.4 micrograms/g in the muscles, 1.4 micrograms/g in the skin and 0.34 micrograms/g in the bones). The study showed that ciprofloxacin was a highly efficient antimicrobial agent in the treatment of the complicated wound infections and the prophylaxis of the purulent complications during the postoperative period in the patients operated on gastrointestinal organs.

[Clinico-laboratory evaluation of the effectiveness of the new aminoglycoside antibiotic brulamycin (tobramycin) in treating surgical infections]. / Kliniko-laboratornaia otsenka éffektivnosti novogo antibiotika-aminoglikozida brulamitsina (tobramitsin) v lechenii khirurgicheskoi infektsii.

The clinico-laboratory estimation of brulamycin in the treatment of 50 patients with severe wound infections showed its high efficacy with respect to gram-negative microflora and in particular Ps. aeruginosa (94 per cent of the sensitive strains). Satisfactory into the affection foci and a long-term maintenance of its therapeutic levels in the host allowed one to recommend the antibiotic for the treatment of patients with complicated purulent affections and first of all systemic infections.

[Clinical effectiveness of carbenicillin in suppurative inflammatory processes of varying localization]. / Klinicheskaia éffektivnost' karbenitsillina pri gnoino-vospalitel'-nykh protsessakh razlichnoi lokalizatsii.

The study on sensitivity of clinical strains of the causative agents of purulent infections to carbenicillin showed that 34.6% of the staphylococcal strains, 48.1% of the E. coli strains and 40.3% of the Proteus strains were sensitive to the antibiotic. The strains of Ps. aeruginosa were characterized by moderate sensitivity to carbenicillin. The MTC for most of the isolates ranged within 25-128 microgram/ml. High therapeutic efficacy of carbenicillin in treatment of cases with purulent inflammatory processes of various localization was shown. Positive results were obtained in 82.5% of the adults and 76.2% of the premature infants treated with carbenicillin. A satisfactory therapeutic effect was observed in the cases with sepsis, diffuse purulent peritonitis and abscessing pneumonia treated with carbenicillin in combination with gentamicin.